Pelthos Therapeutics
PTHS
15 hedge funds and large institutions have $27.9M invested in Pelthos Therapeutics in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, reducing their positions, and 3 closing their positions.
115% more capital invested
Capital invested by funds: $13M → $27.9M (+$14.9M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
13.93% more ownership
Funds ownership: 15.21% → 29.14% (+14%)
7% more funds holding
Funds holding: 14 → 15 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.58M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$2.25M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$1.71M |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$1.01M |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$418K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$23.2K |
| 2 |
Citigroup
New York
|
-$28 |
| 3 |
JP Morgan Chase
New York
|
-$28 |
PTHS Hedge Fund Activity: Q4 2025 in Review
15 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q4 2025, worth a combined $27.9M — up 115% from $13M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PTHS positions and 3 closed out — a net gain of 1 holder — while 10 added to existing stakes and 0 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $5.58M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $23.2K sold.
- 15 institutional investors held Pelthos Therapeutics (PTHS) as of Q4 2025, up from 14 in Q3 2025.
- Funds reported $27.9M of Pelthos Therapeutics stock for Q4 2025, up 115% quarter-over-quarter.
- 4 funds opened new Pelthos Therapeutics positions in Q4 2025 and 3 closed out, a net change of +1 holder.
- The largest Pelthos Therapeutics buyer in Q4 2025 was Ikarian Capital, an estimated $5.58M added.
- The largest Pelthos Therapeutics seller in Q4 2025 was Tower Research Capital (TRC), an estimated $23.2K sold.
Based on aggregated 13F filings for Q4 2025.